Navigation Links
NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference
Date:3/19/2013

BETHESDA, Md., March 19, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Linda F. Powers , the Company's Chairman and Chief Executive Officer, will be presenting at the 25th Annual ROTH Conference at 8:30 a.m. PDT on Wednesday, March 20, 2013, at the Ritz-Carlton, Laguna Niguel, Dana Point, California.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

Ms. Powers' presentation will discuss the Company's lead Phase III trial with DCVax-L for brain cancer, including guidance on enrollment, progress in Europe, and anticipated timelines for major milestones.  Ms. Powers will also discuss the Company's pending Phase I/II trial with DCVax-Direct for all solid tumor cancers that are inoperable, which is preparing to launch in Q2.  Ms. Powers will comment on the Company's key strengths and differentiation in the immune therapy space, and will announce certain new developments.

The presentation will take place in Track 8 of the conference, in The Promenade – White Room, and will be available by web cast at http://wsw.com/webcast/roth27/nwbo/.  The webcast will remain available for 90 days following the presentation.  It will also be available on the NW Bio Website starting on Thursday, March 21, 2013, at www.nwbio.com.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more e
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. At RSNA, DR Systems Will Exhibit RIS, Reporting, Peer Review Systems
2. Nucleic Acids Research Journal Publishes Sapphire Energy Peer-Reviewed Research Paper on a Chloroplast Genome From Green Algae
3. Unigenes 2011 Year in Review - Key Elements in Place to Address Debt in 2012
4. FDAs Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012
5. Nonprofit Consortium Publishes Review of Skullcap Adulteration
6. Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
7. Vitamin D Deficiency Disorders Global Clinical Trials Review, H2, 2012
8. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Second Quarter 2012 Financials
9. Inflammatory Bowel Disease Global Clinical Trials Review, H2, 2012
10. Alzheimers Therapeutics Reviewed by NeuroPerspective
11. Peer Reviewed Clinical Study Shows New Blood Test More Accurately Predicts Risk Of A Heart Attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ) ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.17 billion by ... 2014-2020 The near future will bring Biomedical ... each individual. These sensors can be set to trigger ...
(Date:8/31/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") ... to announce that its wholly owned subsidiary, Portage Pharmaceuticals ... to an Investigational New Drug (IND) application for the ... recently completed a study in a rat model of ... significant efficacy and a more rapid onset of action ...
(Date:8/31/2015)... Aug. 31, 2015 LabStyle Innovations Corp. ... Solution, today announced it recently closed a round ... be used to support the global rollout and ... mobile, cloud-based, diabetes management solution that includes novel ... blood glucose monitoring device, and for working capital ...
(Date:8/31/2015)... ... ... Proove Biosciences, Inc. is a finalist for the Outstanding Tech Company category of ... its 22nd year, this premier awards event celebrates the best in Orange County’s technology ... world. The OC Tech Alliance will announce all winners at a gala dinner on ...
Breaking Biology Technology:Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4
... FRANCISCO, Calif., May 8 Anesiva,Inc. (Nasdaq: ... and accomplishments,for the first quarter ended March ... its,commercialization activities for FDA-approved Zingo(TM) (lidocaine,hydrochloride monohydrate) ... development milestones for Adlea(TM), the company,s long-acting,localized, ...
... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), a ... to participate in the Bank of America,2008 Health ... in Las Vegas,Nevada., Dr. William Hunter, Angiotech,s ... on Wednesday, May 14, beginning at approximately,4:00 pm ...
... highlights Volcano commitment to intravascular imaging ... opens up new clinical and research applications, ... Corporation (Nasdaq: VOLC ), a leading manufacturer ... and Optical,Coherence Tomography (OCT) products designed to enhance ...
Cached Biology Technology:Anesiva Announces First Quarter 2008 Financial Results 2Anesiva Announces First Quarter 2008 Financial Results 3Anesiva Announces First Quarter 2008 Financial Results 4Anesiva Announces First Quarter 2008 Financial Results 5Anesiva Announces First Quarter 2008 Financial Results 6Anesiva Announces First Quarter 2008 Financial Results 7Anesiva Announces First Quarter 2008 Financial Results 8Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter 2Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter 3Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter 4
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
(Date:8/12/2015)... Minn. , Aug. 12, 2015   MedNet ... supports the entire spectrum of clinical research, is proud ... , the company,s comprehensive SaaS-based eClinical technology platform, has ... during the first two quarters of 2015.   Q2 ... second largest quarters measured by contract value sold in ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, ... expected revenues in 2015 that relate to sales of FPC1155 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... smartphone manufacturer in China and ... 155 for Z1 , ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... This release is available in German . ... To defend themselves, they have developed sophisticated chemical defense ... cress ( Arabidopsis thaliana ), produce glucosinolates (mustard oil ... different kinds of these molecules; they have a similar ...
... such as the Japan earthquake can be revealed in ... to a psychology expert at Queen Mary, University of ... Mary, University of London, and author of Controlling Uncertainty: ... had a devastating immediate effect on tens of thousands ...
... Using skin cells from adult siblings with schizophrenia and ... researchers have created induced pluripotent stem cells (iPS cells) using ... February 22 in Molecular Psychiatry , the team confirms ... mutations in the gene named Disrupted In Schizophrenia 1, or ...
Cached Biology News:Production of mustard oils: On the origin of an enzyme 2Production of mustard oils: On the origin of an enzyme 3Psychological impact of Japan disaster will be felt 'for some time to come' 2Johns Hopkins team creates stem cells from schizophrenia patients 2Johns Hopkins team creates stem cells from schizophrenia patients 3
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
... PF 2D is an automated, two-dimensional fractionation ... mixtures. Part of Beckman Coulters ProteomeLab ... results in just hours. The system ... in cell lysates, addressing a key challenge ...
... Rapid-Screen cDNA Library Panels were designed for ... sets of PCRs to identify the desired ... performed in a 96-well "Master Plate," where ... clones. Having identified the positive well(s) by ...
... HORIBA Jobin Yvons Protein 295 ex ... a protein sample in only a few ... the amino acids tyrosine and tryptophan, the ... powerful NanoLED-17, a pulsed diode emitting 295 ...
Biology Products: